Earnings Call · Q4 FY2023·2024-02-27

Q4 23EPS +6.67%·Rev n/aQ3 23EPS -10.26%·Rev n/aQ2 23EPS -2.70%·Rev n/aQ1 23EPS +2.86%·Rev n/a⚠ consensus missing

RECURSION PHARMACEUTICALS, INC. RXRX

Chris Gibson — Co-Founder and CEO

+5.1%1d on move date+5.0% vs SPY3d−8.8%5d−16.7%

Research tier

Behavioral profile computed for this call's speaker on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RXRX calls or request research access.

More RXRX calls Browse calls Request research access